These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

959 related articles for article (PubMed ID: 17128426)

  • 1. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
    Whitehead J; Matsushita T
    Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.
    Tan M; Xiong X; Kutner MH
    Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequentist evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative views on setting clinical trial futility criteria.
    Gallo P; Mao L; Shih VH
    J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
    Yi J; Fang L; Su Z
    Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of methods for futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size and the probability of a successful trial.
    Chuang-Stein C
    Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
    Polley MY; Cheung YK
    Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues in the use of adaptive clinical trial designs.
    Emerson SS
    Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial.
    Hughes S; Cuffe RL; Lieftucht A; Garrett Nichols W
    Pharm Stat; 2009; 8(1):25-37. PubMed ID: 18383194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of two methods for adaptive interim analyses in clinical trials.
    Wassmer G
    Biometrics; 1998 Jun; 54(2):696-705. PubMed ID: 9629649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.